Entod Pharmaceuticals has recently inaugurated its new state-of-the-art R&D facility in Navi Mumbai to further enhance their innovation capability.

The R&D centre was inaugurated by the  group chairman Kishore Masurkar. “We dedicate this research facility to our founder, the late G V Masurkar on the occasion of his 100th birth anniversary year, whose passion for pharmaceutical research, therapeutic innovation & entrepreneurship made him into a pharmaceutical visionary & pioneer of his times”, Kishore Masurkar said.

The advanced research facility is approved by the Department of Scientific & Industrial Research (DSIR) and will focus on ophthalmic, ENT & dermatology formulation development. It will allow the corporation to further engage in new product development, formulation and molecular research.

“The R&D expansion broadens our presence in the country while also acknowledging the country’s specialised capabilities and potential. India has a very mature pharmaceutical market. If Indian pharmaceutical businesses wish to advance in terms of value, they should concentrate on how to deepen their own R&D and inventions. With the G20 presidency, India has an opportunity to set the global agenda and promote inclusive and sustainable industrialisation and foster innovation. In particular, we feel that India's G20 Presidency will encourage innovation and substantially increase the numbers of researchers as well as public and private spending on R&D. In view of India’s G20 Presidency, we believe that digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023” said Nikkhil K Masurkar, CEO, Entod Pharma.